… into other forms of genetic blindness Validate and expand Axiomer ® : Further validate and expand ProQR's proprietary Axiomer ® RNA editing platform through first development … QR-1123, QR-421a, QR-411a, QR-504, the potential of our Axiomer ® editing platform, our plans and timing of …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome